A US court decision has gone against Novo Nordisk in a dispute over how a competing obesity medicine was advertised. The case keeps evidence standards for weight-loss claims in focus.
Obesity medicine advertising faces closer legal scrutiny
The latest US ruling highlights how claims comparing weight-loss treatments can trigger disputes over evidence, consumer information and drug marketing.